^
    Back
    Association details:
    Biomarker:PTPN11 mutation + TMB-H
    Cancer:Melanoma
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASCO 2021
    Title:

    Association of PTPN11 mutation with tumor mutation burden and survival in melanoma patients treated with immune checkpoint inhibitors

    Published date:
    05/19/2021
    Excerpt:
    ...PTPN11 mutation resulted in significantly longer OS (33.6 vs 8.5 months; HR, 0.16; p = 0.037) and an increasing trend on PFS...This study shows that PTPN11 mutation may serve as a potential positive biomarker of ICIs in melanoma since it relatively correlated with higher TMB.
    DOI:
    10.1200/JCO.2021.39.15_suppl.e21596